YPSN logo

Ypsomed Holding AG Stock Price

SWX:YPSN Community·CHF 4.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

YPSN Share Price Performance

CHF 337.00
-77.50 (-18.70%)
35.8% undervalued intrinsic discount
CHF 525.00
Fair Value
CHF 337.00
-77.50 (-18.70%)
31.9% undervalued intrinsic discount
CHF 495.00
Fair Value
Price CHF 337.00
AnalystHighTarget CHF 495.00
AnalystConsensusTarget CHF 449.37
AnalystLowTarget CHF 330.32

YPSN Community Narratives

AnalystHighTarget·Updated
Fair Value CHF 525 35.8% undervalued intrinsic discount

Connected Self-Injection Devices Will Redefine Chronic Care Globally

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value CHF 449.37 25.0% undervalued intrinsic discount

GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystLowTarget·Updated
Fair Value CHF 359.75 6.3% undervalued intrinsic discount

Overcapacity And Regulatory Challenges Will Limit Future Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent YPSN News & Updates

Ypsomed Holding (VTX:YPSN) Might Have The Makings Of A Multi-Bagger

Aug 20
Ypsomed Holding (VTX:YPSN) Might Have The Makings Of A Multi-Bagger

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

Aug 07
Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt

Jul 24
We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt

Do Ypsomed Holding's (VTX:YPSN) Earnings Warrant Your Attention?

Jul 11
Do Ypsomed Holding's (VTX:YPSN) Earnings Warrant Your Attention?

Is Now An Opportune Moment To Examine Ypsomed Holding AG (VTX:YPSN)?

Jun 11
Is Now An Opportune Moment To Examine Ypsomed Holding AG (VTX:YPSN)?

Ypsomed Holding AG Key Details

CHF 748.9m

Revenue

CHF 456.8m

Cost of Revenue

CHF 292.1m

Gross Profit

CHF 204.6m

Other Expenses

CHF 87.5m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Nov 12, 2025
Earnings per share (EPS)
6.41
Gross Margin
39.00%
Net Profit Margin
11.68%
Debt/Equity Ratio
39.3%

Ypsomed Holding AG Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and fair value.

2 Risks
4 Rewards

About YPSN

Founded
1984
Employees
2644
CEO
Simon Michel
WebsiteView website
www.ypsomed.com

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Swiss Market Performance

  • 7 Days: 4.0%
  • 3 Months: 3.4%
  • 1 Year: 3.0%
  • Year to Date: 5.8%
The market has climbed by 4.0% over the past week, with every sector up and the Healthcare sector leading the way. As for last year, the market performance has been flat. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›